BACKGROUND:Nucleoside reverse-transcriptase inhibitor (NRTI)-related mitochondrial toxicity has been suggested as a key factor in the induction of antiretroviral-related lipoatrophy. This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution. METHODS: A multicenter, prospective, randomized trial assessed the efficacy and tolerability of switching to lopinavir-ritonavir plus nevirapine (nevirapinegroup; n = 34), compared with lopinavir-ritonavir plus 2 NRTIs (controlgroup; n = 33) in a group of human immunodeficiency virus-infected adults with virological suppression. A subset of 35 individuals (20 from the nevirapine group and 15 from the control group) were evaluated for changes in the mitochondrial DNA (mtDNA) to nuclear DNA ratio and cytochrome c oxidase (COX) activity after NRTI withdrawal. Dual-energy X-ray absorptiometry (DEXA) scans were used to objectively quantify fat redistribution over time. RESULTS: The nevirapine group experienced a progressive increase in mtDNA content (a 40% increase at week 48; P = .039 for comparison between groups) and in the COX activity (26% and 32% at weeks 24 and 48, respectively; P = .01 and P = .09 for comparison between groups, respectively). There were no statistically significant between-group differences in DEXA scans at week 48, although a higher fat increase in extremities was observed in the nevirapine group. No virologic failures occurred in either treatment arm. CONCLUSIONS: Switching to a nucleoside-sparing regimen of nevirapine and lopinavir-ritonavir maintained full antiviral efficacy and led to an improvement in mitochondrial parameters, which suggests a reversion of nucleoside-associated mitochondrial toxicity. Although DEXA scans performed during the study only revealed slight changes in fat redistribution, a longer follow-up period may show a positive correlation between reduced mitochondrial toxicity and a clinical improvement of lipodystrophy.
RCT Entities:
BACKGROUND:Nucleoside reverse-transcriptase inhibitor (NRTI)-related mitochondrial toxicity has been suggested as a key factor in the induction of antiretroviral-related lipoatrophy. This study aimed to evaluate in vivo the effects of NRTI withdrawal on mitochondrial parameters and body fat distribution. METHODS: A multicenter, prospective, randomized trial assessed the efficacy and tolerability of switching to lopinavir-ritonavir plus nevirapine (nevirapine group; n = 34), compared with lopinavir-ritonavir plus 2 NRTIs (control group; n = 33) in a group of human immunodeficiency virus-infected adults with virological suppression. A subset of 35 individuals (20 from the nevirapine group and 15 from the control group) were evaluated for changes in the mitochondrial DNA (mtDNA) to nuclear DNA ratio and cytochrome c oxidase (COX) activity after NRTI withdrawal. Dual-energy X-ray absorptiometry (DEXA) scans were used to objectively quantify fat redistribution over time. RESULTS: The nevirapine group experienced a progressive increase in mtDNA content (a 40% increase at week 48; P = .039 for comparison between groups) and in the COX activity (26% and 32% at weeks 24 and 48, respectively; P = .01 and P = .09 for comparison between groups, respectively). There were no statistically significant between-group differences in DEXA scans at week 48, although a higher fat increase in extremities was observed in the nevirapine group. No virologic failures occurred in either treatment arm. CONCLUSIONS: Switching to a nucleoside-sparing regimen of nevirapine and lopinavir-ritonavir maintained full antiviral efficacy and led to an improvement in mitochondrial parameters, which suggests a reversion of nucleoside-associated mitochondrial toxicity. Although DEXA scans performed during the study only revealed slight changes in fat redistribution, a longer follow-up period may show a positive correlation between reduced mitochondrial toxicity and a clinical improvement of lipodystrophy.
Authors: Todd Hulgan; Asha R Kallianpur; Yan Guo; Jill S Barnholtz-Sloan; Haley Gittleman; Todd T Brown; Ronald Ellis; Scott Letendre; Robert K Heaton; David C Samuels Journal: J Acquir Immune Defic Syndr Date: 2019-04-01 Impact factor: 3.731
Authors: Maile Y Karris; Sonia Jain; Tyler R C Day; Josué Pérez-Santiago; Miguel Goicoechea; Michael P Dubé; Xiaoying Sun; Celsa Spina; Eric S Daar; Richard H Haubrich; Sheldon Morris Journal: HIV Clin Trials Date: 2017-01-30
Authors: Ylva Terelius; Robert A Figler; Svetlana Marukian; Maria S Collado; Mark J Lawson; Aaron J Mackey; David Manka; Charles W Qualls; Brett R Blackman; Brian R Wamhoff; Ajit Dash Journal: Chem Biol Interact Date: 2015-12-02 Impact factor: 5.192
Authors: Elżbieta Jabłonowska; Piotr Pulik; Anna Kalinowska; Jacek Gąsiorowski; Miłosz Parczewski; Monika Bociąga-Jasik; Elżbieta Mularska; Łukasz Pulik; Ewa Siwak; Kamila Wójcik Journal: Arch Med Sci Date: 2016-09-22 Impact factor: 3.318